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Abstract
Alzheimer’s disease (AD) is the main cause of dementia in our increasingly aging population. The debilitating cognitive and
behavioral symptoms characteristic of AD make it an extremely distressing illness for patients and carers. Although drugs
have been developed to treat AD symptoms and to slow disease progression, there is currently no cure. The incidence of AD
is predicted to increase to over one hundred million by 2050, placing a heavy burden on communities and economies, and
making the development of effective therapies an urgent priority. Two proteins are thought to have major contributory
roles in AD: the microtubule associated protein tau, also known as MAPT; and the amyloid-beta peptide (A-beta), a cleavage
product of amyloid precursor protein (APP). Oxidative stress is also implicated in AD pathology from an early stage. By
targeting eIF4A, an RNA helicase involved in translation initiation, the synthesis of APP and tau, but not neuroprotective
proteins, can be simultaneously and specifically reduced, representing a novel avenue for AD intervention. We also show
that protection from oxidative stress is increased upon eIF4A inhibition. We demonstrate that the reduction of these
proteins is not due to changes in mRNA levels or increased protein degradation, but is a consequence of translational
repression conferred by inhibition of the helicase activity of eIF4A. Inhibition of eIF4A selectively and simultaneously
modulates the synthesis of proteins involved in Alzheimer’s disease: reducing A-beta and tau synthesis, while increasing
proteins predicted to be neuroprotective.
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Introduction
Alzheimer’s disease (AD) is the main cause of dementia in our
aging population, and currently there is no effective treatment. At
the cellular and molecular level, AD is characterized by the
presence of extracellular plaques of the peptide amyloid-beta (Ab),
and also by intracellular neurofibrillary tangles of tau protein
(reviewed in [1]). The precise molecular basis of AD has been the
subject of an enormous amount of research, and the details are still
the subject of some disagreement. Nevertheless, it is clear that
amyloid precursor protein (APP, NM_000484) and tau
(NM_016835) play important roles in disease progression, and
both have been identified as promising therapeutic targets
[2,3,4,5,6,7]. Reducing the levels of APP and tau has been shown
to slow disease progress in animal models, and current therapies
target disease models based on these two proteins, albeit with
incomplete success. For example, even a modest reduction of
soluble Ab has been shown to have a dramatic effect on amyloid
plaque formation in animal models [8], and reduction of tau
protein levels ameliorates the neurotoxic effects of Ab in mice
overexpressing APP [9]. Oxidative stress is also implicated as an
important factor in AD progression, and increasing the levels of
proteins involved in reducing oxidative stress are predicted to
impact beneficially on AD symptoms (reviewed in [10,11]).
Oxidative stress is likely an early event in AD progression, and
has been shown to increase Ab formation by increasing APP levels
and processing [12,13]. Ab itself has oxidant properties, leading to
a positive feedback loop and further increase in Ab levels [14,15].
In addition to increasing the likelihood of plaque formation,
increased Ab levels also lead to hyperphosphorylation of tau
protein, an increase in neurofibrillary tangle formation, and
consequent further oxidative stress [14]. Markers of oxidative
stress, including modification of DNA, RNA, lipids and proteins,
are increased in brains of AD patients, and in animal models [11].
In contrast to other cell types, the high metabolic rates and levels
of pro-oxidants, coupled with less efficient anti-oxidant responses,
makes cells of the CNS particularly prone to oxidative stress [10].
In mouse models incorporating both Ab and tau pathologies, Ab
and tau proteins were found to act synergistically to inhibit
mitochondrial oxidative phosphorylation, and increase cellular
levels of reactive oxygen species [16].
The regulation of protein synthesis at the level of translation is
particularly important in neuronal cells for a number of reasons.
Firstly, neurons tend to be metabolically very active, placing heavy
demands on the protein synthesis machinery. Secondly, the
lengths of many of the cells of the CNS means that controlling
the rates of translation of localized mRNA pools will likely offer
faster and more flexible control of gene expression than changes in
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transport of either newly synthesized mRNA or protein.
The most abundant eukaryotic translation initiation factor is
eIF4A, an RNA helicase which facilitates translation initiation by
unwinding otherwise inhibitory mRNA structure. The 59 untrans-
lated regions (59 UTRs) of APP and tau mRNAs are known to be
long and structured, and hence represent a barrier to the initiating
ribosome during protein synthesis. Additionally, both APP and tau
mRNAs are able to initiate translation in a cap-independent
manner via internal ribosome entry sites (IRESes) [17,18]. We
have recently shown that eIF4A is required for a number of
mammalian IRESes [19]. We therefore propose that inhibiting
eIF4A will reduce the efficiency of APP and tau protein synthesis,
but not that of housekeeping proteins. Interestingly, it has been
reported that decreasing the stability of RNA structures within
portions of the APP 59 UTR is correlated with increased
expression [20]. We have used hippuristanol, a potent and specific
inhibitor of eIF4A, to test this model. Hippuristanol, a poly-
oxygenated steroid isolated from the Gorgonian Isis hippuris has
been shown to be a potent and specific inhibitor of the helicase,
RNA binding and ATP hydrolysis properties of eIF4A [21]. APP,
tau and Ab levels were found to be reduced in hippuristanol
treated SH-SY5Y cells, whereas proteins involved in defence from
oxidative stress are increased (e.g. SOD1, TXN and NDUFB2).
We show that these changes are due to differences in de novo
protein synthesis rates mediated via the 59 UTRs, and not to
variation in transcription or protein turnover, and that cell
viability under oxidative insult is increased.
Results
Polysomal redistribution of mRNAs following
hippuristanol treatment
To test the effects of eIF4A inhibition on the translation of
proteins involved in AD, hippuristanol was used to treat cultured
mammalian cells for ten minutes (HeLa, N2a and SH-SY5Y), and
the polysomal associations of APP, tau, TXN (thioredoxin;
NM_003329), SOD1 (superoxide dismutase 1; NM_000454),
NDUFB2 (NADH dehydrogenase (ubiquinone) 1 beta subcom-
plex, 2; NM_004546), b-actin (NM_001101) and PABP (poly-A
binding protein; NM_002568) were each determined in treated
and control cells using sucrose density gradient centrifugation
followed by northern analysis (figure 1). Sucrose density gradient
centrifugation separates mRNAs according to their ribosomal
load, with actively translated (polysomal) mRNAs partitioning
towards the bottom of the gradient due to their increased density,
whereas subpolysomal mRNAs are less dense and partition
towards the top of the gradient. The polysomal distributions of
b-actin and PABP were unchanged following hippuristanol
treatment (figure 1A), however, it is clear that the mRNAs
encoding APP and tau shift subpolysomally following hippurista-
nol treatment indicating a reduction in translation of these
transcripts (figure 1B). In contrast, mRNAs encoding SOD1,
TXN, and NDUFB2 (which have been proposed to have
neuroprotective roles [22,23,24] increase in polysomal association
(figure 1C).
Changes in AD associated protein levels in hippuristanol
treated cells
To determine whether these changes in polysomal association
result in alterations to the cellular concentrations of proteins
involved in AD, western analysis was performed using antibodies
specific to APP, tau, TXN, Ab and b-actin (figure 2). APP
concentrations in SH-SY5Y cells were markedly reduced at 4 and
24 hours following 10 mM hippuristanol treatment, and tau
protein levels showed a reduction at 4 hours followed by a partial
recovery by 24 hours following treatment (figure 2A). Conversely,
TXN levels increased slightly 4 hours following hippuristanol
treatment and returned to control levels within 24 hours. APP is
cleaved to generate the Ab peptide, and it is the aberrant
aggregation of this peptide into extracellular plaques that is
characteristic of AD pathology. Western blotting of concentrated
media shows a reduction of secreted Ab peptide 24 hours
following hippuristanol treatment of SH-SY5Y cells (figure 2A).
Treatment with 20 mM and 30 mM hippuristanol increases this
reduction of APP, tau and Ab levels (data not shown).
Hippuristanol reduces APP and tau protein synthesis
To establish whether the observed changes in APP, tau and
TXN protein levels in hippuristanol treated cells were due to
changes in new protein synthesis rather than turnover, synthesis
rates were measured by immunoprecipitation following
35S-
methionine labeling of SH-SY5Y cells (figure 2B). Levels of APP
and tau synthesis were markedly reduced following hippuristanol
treatment, whereas TXN synthesis was unaffected. To determine
the effects of hippuristanol on extracellular levels of Ab,
immunoprecipitation from the media of hippuristanol treated
and control SH-SY5Y cells was performed using an antibody
specific to Ab following
35S-methionine labeling. A decrease in
extracellular Ab was observed by western blotting of the media of
treated cells (figure 2B) and also by ELISA (figure 2C).
Changes in mRNA levels are not responsible for the
observed changes in protein levels
To confirm that the changes in the levels of these proteins were
due to translational rather than transcriptional effects, northern
analysis of total cellular RNA was performed (figure 3). mRNA
levels for APP, tau and TXN did not decrease following
hippuristanol treatment for 4 or 24 hours, in parallel with the b-
actin control, confirming that hippuristanol was not inhibiting
transcription.
The 59 UTRs of APP and tau are sufficient to mediate
repression in a luciferase reporter model
Our model predicts that the specific reduction of APP and tau
protein levels following eIF4A inhibition depends on features in
the 59 UTRs of these mRNAs. To test this, we cloned the 59 UTR
sequences of APP, tau, SOD1 and TXN upstream of the firefly
luciferase open reading frame in pGL4.14 Following co-transfec-
tion of these constructs with a control Renilla luciferase open
reading frame containing a short unstructured 59 UTR into SH-
SY5Y cells we observed that expression from the APP and tau
59UTR constructs was markedly reduced (to 21% and 8% of
controls respectively) following hippuristanol treatment, but the
SOD1 and TXN 59 UTR containing plasmids were relatively
resistant to this inhibition (75% and 76% of controls
respectively)(figure 4). To eliminate the possibility that cryptic
promoter elements within these 59 UTR sequence could
undermine these assays, the cmv promoter in these constructs
was deleted by AseI restriction digestion and religation, which
completely ablated luciferase activity (data not shown).
eIF4A inhibition increases cell proliferation in response to
oxidative stress
SH-SY5Y cells were treated with hydrogen peroxide to induce
oxidative stress. Upon treatment of control cells with hydrogen
peroxide, there is a small but reproducibly significant reduction in
eIF4A Inhibition and AD
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significantly higher viability upon cells undergoing oxidative stress
compared with those in which eIF4A is uninhibited (figure 5).
Discussion
We have demonstrated that a small molecule inhibitor of
protein synthesis can specifically down-regulate APP and tau
protein levels in cultured cells of neurological origin. In addition,
secreted Ab levels are also reduced. In contrast, the polysomal
association and protein levels of control genes predicted to have
neuroprotective functions are resistant to this inhibition. Despite
vast amounts of research, current treatment for Alzheimer’s
disease relies on alleviating symptoms rather than reversing disease
progression. The search for novel approaches to AD therapy is,
therefore, as important as ever.
Upon treatment with hippuristanol, mRNAs encoding APP
and tau become associated with fewer ribosomes, indicating a
Figure 1. eIF4A inhibition changes the polysomal association of certain mRNAs. Cultured cells (SH-SY5Y, N2a or HeLa) were treated with
10 mM hippuristanol (+) or DMSO control (2) for 10 minutes, lysed and mRNA fractionated on a 10%–50% sucrose gradient. OD260nm absorbance
was determined with simultaneous 1 ml fraction collection to determine subpolysomal and polysomal fractions (fraction number and subpolysomal
or polysomal association indicated). Northern analysis was performed to determine the positions of mRNAs for: A Actin and PABP which do not
change in polysome associations; B APP and tau which become less polysomally associated; C TXN, NDUFB2 and SOD1 which become more
polysomally associated. Relative levels of RNA are indicated by dark grey (DMSO control) and light grey (10 mM hippuristanol) bars beneath each
fraction, as percentages of the total amount RNA in each gradient.
doi:10.1371/journal.pone.0013030.g001
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e13030Figure 2. Expression of proteins associated with AD is altered by eIF4A inhibition. A Western analysis was performed on lysates from SH-
SY5Y cells treated with 10 mM hippuristanol (+) or DMSO control (2) for 4 or 24 hours with antibodies specific to APP, TAU and TXN (bands of around
70 kDa, 60 kDa and 12–14 kDa respectively). The 70 kDa band was detected by the APP specific antibody representing a cleavage product specific to
K+ isoforms [53]. Secreted A-beta was measured by western analysis of cell culture media. The 56 kDa product is interpreted as an aggregate of A-
beta, as has previously been reported for western analysis of brain tissue [51]. Protein levels were normalized to actin, and mean relative proportions
of protein with standard errors are indicated beneath each gel image. Significant differences (p#0.05 by t-test) are indicated by asterisks. B.
Immunoprecipitation following
35S-methionine labeling demonstrates a reduction in novel synthesis of APP, TAU but not TXN when SH-SY5Y cells are
treated with 10 mM hippuristanol. Secreted A-beta levels are also reduced, as determined by immunoprecipitation from cell culture medium. Mean
relative proportions of protein with standard errors are indicated beneath each gel image. Significant differences (p#0.05 by t-test) are indicated by
asterisks. C. Secreted A-beta levels in the medium of 9610
5 SH-SY5Y cells were assayed by ELISA 24 hours following treatment with 10 mM
eIF4A Inhibition and AD
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primarily at initiation, in which a complex of translation factors
assembles at the 59 end of an mRNA molecule to recruit the
translational machinery [25]. 59 UTRs of mRNAs vary signifi-
cantly in their length, and in their potential to form secondary
structure [26]. Increased 59 UTR length and structure represents a
barrier to the scanning ribosomal subunit, and increases the
requirement for eIF4A, a DEAD-box RNA helicase which forms
part of the initiation complex [27], and is the most abundant
translation initiation factor. To confirm that the 59 UTRs of APP
and tau are particularly dependent on eIF4A we used a luciferase
reporter system in which candidate 59 UTRs are positioned
upstream of a luciferase open reading frame.
The requirement for eIF4A in experimental translation systems
has been shown to be proportional to 59 UTR structure [27], and
the small number of mRNAs that have been shown to be regulated
by eIF4A contain long structured 59 UTRs [19,28,29,30,31].
Additionally, experiments involving the APP 59 UTR upstream of
a reporter open reading frame showed an inverse correlation
between 59 UTR structure and reporter expression [20]. Analysis
of mammalian mRNA structure has determined that messages
predicted to be ‘‘difficult’’ to translate due to increased length,
structure and other regulatory features in the 59 UTR tend to
encode regulatory rather than housekeeping proteins, and it is this
subset of mRNAs that will be particularly reliant on eIF4A for
efficient expression [32]. Consistent with this, hippuristanol
Figure 3. mRNA levels do not account for the change in protein levels following hippuristanol treatment. Northern analysis 4 or
24 hours following 10 minutes 10 mM hippuristanol treatment, using probes specific to APP, TAU, Actin and TXN, indicates no significant decrease in
these mRNA levels. Mean relative proportions of RNA with standard errors are indicated in the charts beneath each gel image.
doi:10.1371/journal.pone.0013030.g003
hippuristanol (+), demonstrating a modest but reproducible decrease in comparison to control cells (2). Means and standard errors of 6 replicates are
shown p=0.05.
doi:10.1371/journal.pone.0013030.g002
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used, and has a specific and reversible effect on translation [21].
We therefore envisage a model in which inhibition of eIF4A
reduces the expression of a subset of regulatory and stress response
genes, while leaving housekeeping functions unaffected. The
increased polysomal association of TXN, SOD1 and NDUFB2
indicates that RNA-RNA interactions necessary for optimal
translation may be stabilized in the absence of active eIF4A.
eIF4A may have a particular role in neuronal translation, as
suggested by the restriction of expression of BC1/BC200 RNA to
neuronal tissue, where it is thought to interact with and inhibit
eIF4A [33]. Patterns of BC200 expression are markedly different
in the brains of people with Alzheimer’s disease in comparison
with those of the healthy elderly, although whether this is a
response to AD or a contributing factor is unclear [34].
Additionally, HuD, which is essential for neuronal development,
has recently been found to interact with eIF4A [35]. Two almost
identical, and so far functionally indistinguishable, isoforms of
eIF4A exist in mammalian cells: eIF4AI and eIF4AII. eIF4AI
expression is upregulated during retinoic acid induced neural
differentiation of P19 cells indicating a specific role in translation
of neuronal mRNAs [36]. eIF4AII has been implicated in neural
patterning where it has been proposed to up-regulate a subset of
mRNAs based on their 59 UTR structure [37]. Data from the
human protein atlas suggest that eIF4AII is more highly expressed
in both glial and neuronal cells than eIF4AI, a pattern also
reflected in malignant gliomas [38]. Additionally, the eIF4AI/II
paralogue, eIF4AIII, which is localized to the nucleus in most cell
types and not usually thought to be involved in translation, is
found to be associated with (cytoplasmic) mRNAs in somatoden-
dritic regions of neurons [39]. eIF4AIII in these cells has been
linked to increased mRNA decay, and eIF4AIII knockdown is
associated with an increase in protein synthesis and increased
synaptic strength. Interestingly, eIF4AIII has been shown to be
inhibitory to eIF4AI/II dependent translation in vitro [40]. We
therefore propose a model in which 59 UTR length and structure
increase the sensitivity of APP and tau mRNAs to eIF4A
inhibition, whereas housekeeping mRNAs and at least a subset
of mRNAs predicted to be neuroprotective are resistant to this
inhibition.
It is known that the mRNAs of tau and APP contain elements in
their 59 UTRs that regulate their translation, including IRESes
[17,18], and it is plausible that these confer an increased
requirement for eIF4A helicase activity to facilitate 40S ribosomal
subunit scanning. We have recently demonstrated such a
requirement for eIF4A for the cellular IRESes of n-myc, l-myc
and c-myc mRNAs [19]. Additionally, at 194 and 320 nts
respectively, the 59 UTRs of APP (NM_000484) and tau
(NM_016835) are long in comparison to those of SOD1, TXN
and NDUFB2 (148, 63 and 64 nts respectively; NM_000454,
NM_003329, NM_004546).
Other modulators of translation initiation are also likely to be
important in regulating gene expression in AD, in particular the
eIF2alpha kinases PKR and PERK, which can, like hippuristanol,
regulate translation initiation. PKR and PERK are two stress
induced eIF2alpha kinases which inhibit global translation rates by
phosphorylating the translation initiation factor eIF2alpha,
preventing eIF2alpha recycling. Active PKR (and inhibited
eIF2alpha) are increased in AD models and in patients’ brains,
and correlate with decreased cognitive ability [41]. PERK is also
increased in AD neurons, where it is associated with an increase in
aberrant tau protein accumulation [42], and Ab production [43].
Interestingly, the PI3 kinase inhibitors wortmannin and LY294002
have been proposed to decrease secreted Ab in a high-throughput
cell based assay, with wortmannin showing similar effects in a
mouse AD model [44]. Although no strong conclusions were
drawn as to the mechanism responsible for this Ab reduction, it is
consistent with inhibition of translation via the mTOR pathway.
SOD1 (superoxide dismutase-1) is responsible for metabolizing
superoxide radicals, and hence protecting cells from oxidative
stress, a proposed causative factor in AD. Overexpression of
SOD1 in neuronal cells protects against the toxic effects of Ab in
cultured neuronal cells [45,46]. In mice models of AD, increased
SOD1 expression ameliorates the cerebrovascular toxicity associ-
ated with APP overexpression [23]. TXN (thioredoxin) is also
Figure 4. Translational inhibition of APP and tau is mediated
via the 59 UTR. Firefly luciferase reporter plasmids containing the 59
UTR of APP, tau, SOD1 or TXN upstream of a destabilized firefly
luciferase open reading frame were transfected into SH-SY5Y cells +/2
10 mM hippuristanol. The dramatic reduction of luciferase expression in
the APP and tau 59 UTR constructs following hippuristanol treatment is
not mirrored by the SOD1 and TXN 59 UTR containing plasmids.
Luciferase activity was normalized to a cotransfected Renilla control
reporter and means and standard errors of at least three replicates are
shown.
doi:10.1371/journal.pone.0013030.g004
Figure 5. Hippuristanol treatment protects cells from oxidative
stress. SH-SY5Y cells were pre-treated with hippuristanol or DMSO
control for 4 hours, followed by 50 mMH 2O2 or control treatment for
two hours. After a 22 hour recovery period, viability was determined by
WST assay. Significant differences (p#0.05 by t-test) are indicated by
asterisks.
doi:10.1371/journal.pone.0013030.g005
eIF4A Inhibition and AD
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neuroprotective roles [24]. TXN expression is lower in the brains
of AD sufferers than in unaffected individuals. Moreover, in
cultured neuronal cells, TXN is oxidized by Ab indicating a role in
defence against Ab mediated oxidative stress. Overexpression of
TXN in cultured neuronal cells can protect against the toxic
effects of Ab [47]. NDUFB2 (NADH-ubiquinone oxidoreductase 1
beta subcomplex, 2) is encoded in the nucleus, but is part of the
multisubunit mitochondrial NADH:ubiquinone oxidoreductase
(complex I), which has been identified as a factor linking oxidative
stress and aging, including cognitive aging [22,48]. Interestingly,
complex I proteins have been found to be deregulated in triple
transgenic AD mice (expressing mutant tau, APP and PS1) which
exhibit both Ab and tau pathologies [16]. In addition, NDUFB2 is
known to be upregulated during ischemic shock, and is proposed
to have a role in regulating cellular oxidant levels [49].
The simultaneous inhibition of APP and tau translation by
eIF4A inhibition, in concert with increased expression of proteins
protective against oxidative stress could therefore represent a new
approach for AD intervention. It is well established that oxidative
stress occurs early in AD pathology, and that neuronal cells are
particularly susceptible to oxidative damage. We have demon-
strated that hippuristanol treatment protects against hydrogen
peroxide treatment in cultured cells, indicating an additional
neuroprotective role for eIF4A inhibitors. We propose that the
nature of the 59 UTRs of the mRNAs tested determines their
response to eIF4A inhibition: the mRNAs encoding APP and tau
contain long structured 59 UTRs, in contrast to those of TXN,
SOD1 and NDUFB2. Moreover, APP and tau 59 UTRs contain
IRES elements, allowing cap-independent translation initiation
[17,18]. Although little is known of the translation factor
requirements for cellular IRESes, we have recently shown that
the myc family of IRESes requires eIF4A for proper function [19].
We can therefore speculate that this may also be the case for the
APP and tau IRESes, and this is currently under investigation. We
propose that housekeeping genes, which tend to have short,
unstructured 59 UTRs are largely unaffected by the concentration
of hippuristanol used. However, it is more difficult to propose an
explanation for the increase in synthesis of the neuroprotective
proteins tested. We can speculate that RNA structure elements (or
RNA:RNA or RNA:protein interactions) in the 59 UTR is
required for optimal translation, and that these are stabilized by
the absence of eIF4A helicase activity, but this remains to be
tested. The involvement of HuD – eIF4A interactions in control of
neuronal genes indicates that interactions of eIF4A with other
proteins may be important [35]. Nevertheless it is clear that eIF4A
inhibition has differential effects on the synthesis of proteins
involved in Alzheimer’s disease, and that these effects could
represent a novel approach to AD intervention.
Materials and Methods
Cell culture
Two 15cm plates of cultured cells (SH-SY5Y, N2a or HeLa)
were used per treatment. Cells were grown to 70% confluency
then treated with 10 mM hippuristanol (a kind gift from Prof Ya-
Ching Chen, National Taiwan University), or DMSO control for
10 minutes, at which point translation elongation was arrested by
the addition of cycloheximide (1 mg/ml) on ice. Cells were lysed
(300 mM NaCl, 15 mM MgCl2, 15 mM Tris-HCl pH 7.5,
0.1 mg ml
21 cycloheximide, 1 mg ml
21 heparin, 1% triton X-
100) then cytoplasmic extract was loaded onto 10%–50% sucrose
gradients (300 mM NaCl, 15 mM MgCl2, 15 mM Tris-HCl
pH 7.5, 0.1 mg ml
21 cycloheximide, 1 mg ml
21 heparin) and
centrifuged at 38,000 rpm for two hours. OD260nm absorbance
was determined with simultaneous 1 ml fraction collection.
Oxidative stress assay: SH-SY5Y cells were pre-treated with
10 mM hippuristanol for 4 hours. Cells were washed twice with
PBS then replaced with media, 10 mM hippuristanol, 50mMH 2O2
(or controls) and incubated at 37uC for 2hours. After this time
treatment media was removed, cells were washed twice and fresh
media only was added to each well. After a 22 hour recovery
period, 10ml WST-1 (Roche, Mannheim, Germany) was added to
the 90ml recovery media in each well and cell viability measured
after 45 minutes following manufacturer’s instructions.
Analysis of mRNA and protein levels
Northern analysis was performed on the gradient fractions to
determine the positions of mRNAs for b-actin, PABP, APP, tau,
SOD1, NDUFB2 and TXN, using probes derived from PCR
products to the coding regions of these genes. Northern analysis of
polysome gradients was quantified using Image Quant (GE
Healthcare), expressing the value for each gradient fraction as a
percentage of the total for the whole gradient. Each experiment
was performed as at least three independent replicates and a
typical example shown. Northern blots of total cellular RNA were
quantified using the gel analysis function of ImageJ [50] and values
for each protein corrected for loading errors by comparison with
actin controls, and expressed as a fraction of paired control
(DMSO) and experimental (10 mM hippuristanol) samples. Means
and standard errors of at least three replicates of each experiment
are shown. Western analysis was performed on lysates from SH-
SY5Y cells treated with 10 mM hippuristanol (+) or DMSO control
(2) for 4 or 24 hours with antibodies specific to APP, Ab, tau,
TXN, and b-actin (Primary antibodies used in this study were all
sourced from Cell Signaling Technology, Beverly, MA, USA: anti-
APP (2452); anti-ß-Amyloid (2454); anti-tau (4019); anti-TXN 1
(2285). Secreted Ab was measured by western analysis of SH-
SY5Y cell culture media. 500ml of medium was taken from each
well of a 12 well plate 24 hours after treatment. Medium was then
concentrated by microcon column (Millipore, Billerica, MA, USA)
to a final volume of 20ml. Four independent biological replicates
were conducted per treatment. A 70 kDa band was detected by
the APP specific antibody representing a cleavage product specific
to K+ isoforms [14]. The 56 kDa product is interpreted as an
aggregate of Ab, as has previously been reported for western
analysis of brain tissue [51]. Western blots were quantified using
the gel analysis function of ImageJ [50], and values for each
protein corrected for loading errors by comparison with tubulin
and actin controls, and expressed as a fraction of paired control
(DMSO) and experimental (10 mM hippuristanol) samples. Means
and standard errors of at least three replicates of each experiment
are shown. Significance was determined by t-test, a p value#0.05
indicated by an asterisk. Immunoprecipitation was performed
following
35S-methionine labelling using the above antibodies, as
described in [52]. Immunoprecipitation experiments were quan-
tified using the gel analysis function of ImageJ [50] and expressed
as a fraction of paired control (DMSO) and experimental (10 mM
hippuristanol) samples. Means and standard errors of at least three
replicates of each experiment are shown. Significance was
determined by t-test, a p value#0.05 indicated by an asterisk.
ELISAs were performed using a kit designed to detect human Ab
1–42 (reference KHB3441, Invitrogen, Paisley, UK), following
manufacturer’s instructions. SH-SY5Y medium for ELISAs was
collected 24 hours following treatment with 10 mM hippuristanol
or DMSO control, before addition of protease inhibitors (EDTA
free, Roche, Basel, Switzerland, plus 25mM NaF) and glycerol
phosphate (50 mM).
eIF4A Inhibition and AD
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Firefly luciferase reporter plasmids were constructed by
inserting the cmv promoter from pGL3.1 (Promega, Madison,
WI), amplified using primers (CMV F, CTGGCCGGTAC-
CTCGCGATGTACGGGCCAGAT and CMV R, CTCGA-
GAAGCTTAAGTTTAAACGCTAGCCAGC), and inserted be-
tween the KpnI and HindIII sites of pGL4.15 and pGL4.80 to
create pGL4.15cmv and pGL4.80cmv respectively. A cloning
intermediate, php15, was created by inserting part of the human
ODC 59 UTR (accession NM_002539) amplified using primers
(ODCHP F, GATTACAAAGCTTCTCGAGGGGCGAATAC-
GAATTCGTCA and ODCHP R, GATTACAAAGCTTT-
TAATTAAGGATCCGTCTTCCCGCCGCC) into the HindIII
site of pGL4.15cmv. TXN and SOD1 59 UTRs were amplified
from SH-SY5Y cDNA using primers (TXN F GATACACTC-
GAGTTTGGTGCTTTGGATCCATT, TXN R GATACAT-
TAATTAACTTGGCTGCTGGAGTCTGAC, SOD1 F GA-
TACACTCGAGGTTTGGGGCCAGAGTGGGCG, SOD1 R
GATACATTAATTAAAACTCGCTAGGCCACGCCGA), and
match nucleotides 1–63 of NM_003329 and 1–148 of
NM_000454 respectively. APP and tau 59 UTRs were synthesised
by Genscript (Piscataway, NJ), to match nucleotides 1–194 of
NM_201414 and 1–320 of NM_001123066 respectively, flanked
by XhoI and PacI restriction sites. Following restriction digestion
with XhoIa n dPacI, these APP, tau, SOD1 and TXN 59 UTR
sequences were inserted between the XhoIa n dPacI sites of php15 to
generate pGL4.15cmvAPP5,pGL4.15cmvtau5,pGL4.15cmvSOD1.5
and pGL4.15cmvTXN5 respectively. 800 ng each of the
pGL4.15cmv[59 UTR] plasmids and control pGL4.80cmv plasmid
was co-transfected into each well of a 24 well plate containing sub-
confluent SH-SY5Y cells. Following recovery for 4 hours, the cells
were split into a 96 well plate, and allowed a further 4 hours recovery.
10 mM hippuristanol or DMSO control was added, and cells harvested
after 4 hours. Luciferase levels were assayed using the Dual Luciferase
Assay (Promega, Madison, WI) following manufacturer’s instructions.
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